Back失智長者拒食恐非單純沒胃口 手拿式餐食改善、留意憂鬱及自殺風險
失智長者拒食恐非單純沒胃口  手拿式餐食改善、留意憂鬱及自殺風險
Health
自由时报58 minutes agoHealth2 min readChinaView translation

失智長者拒食恐非單純沒胃口 手拿式餐食改善、留意憂鬱及自殺風險

醫師提醒拒食可能與憂鬱及自殺風險有關,需多專業團隊整合照護

Quick Look

新營醫院針對失智症長輩拒食問題,推動「手拿式餐食」將正餐設計成方便拿取的小份量,保留長輩自主進食尊嚴。醫師指出拒食可能與忘記進食步驟、餐具操作困難、憂鬱及自殺風險有關,需神經內科、精神科、護理、營養及吞嚥復健團隊整合照護。

AI-generated summary

Why It Matters

日本一項針對208名機構內失智症患者的研究發現,5.9%出現「拒絕將食物放入口中」的行為。衛生福利部新營醫院失智症中心目前收案的250名失智症個案中,也陸續發現長者出現拒食現象。

Font size

新營醫院針對失智症長輩拒食情形,推動「手拿式餐食」,將正餐設計成方便拿取的小份量餐食,保留長輩自主選擇與進食的尊嚴。(圖由新營醫院提供)

〔記者劉婉君/台南報導〕日本一項針對208名機構內失智症患者的研究發現,5.9%出現「拒絕將食物放入口中」的行為,衛生福利部新營醫院失智症中心目前收案的250名失智症個案中,也陸續發現長者出現拒食現象。醫療團隊提醒,失智症長輩拒食可能不只是沒有胃口,而是忘記怎麼吃、無法操作餐具,也可能與憂鬱有關,須留意自殺風險。

新營醫院神經內科醫師莊毓民指出,失智症可能影響記憶、執行功能及動作協調,使長者忘記進食步驟,或因不熟悉筷子、湯匙等餐具操作而感到挫折。牙痛、便秘、感染、譫妄、吞嚥障礙及藥物副作用,也可能造成拒食。

精神科主任許博彥醫師也提醒,如果長者拒食時反覆說出「不想活了」、「吃飽等死」等話語,應留意憂鬱症及自殺意念,進一步評估是否有自傷計畫或立即危險,必要時安排緊急醫療處置。家屬也應避免責備或強迫進食,及早尋求專業協助。

院方借鏡日本介護食品經驗,推動「手拿式餐食」,將正餐設計成方便拿取的小份量餐食,如地瓜條、蛋餅條、軟質豆腐餐點及雞肉營養小丸子等,讓長者可以直接用手拿食物吃,降低使用餐具的負擔,保留自主選擇與進食的尊嚴。但仍須注意吞嚥安全,醫療團隊提醒,圓形、黏稠或彈性較強的食物可能增加噎食風險,有吞嚥困難者應先接受專業評估。

新營醫院失智症中心強調,拒食照護需要整合神經內科、精神科、護理、營養及吞嚥復健團隊,從身體、心理到飲食方式共同介入。

自由電子報關心您︰自殺不能解決問題,勇敢求救並非弱者,社會處處有溫暖,一定能度過難關。

安心專線:1925

生命線協談專線:1995。

張老師專線:1980

Open Questions

  • 手拿式餐食推動後,長者拒食情況是否有可量化的改善?
  • 新營醫院失智症中心的整合照護模式是否會推廣至其他醫療院所?

Related Topics

This article was originally published by 自由时报.

Related Stories

Urinary incontinence is not the fate of aging! 60-year-old woman regains laughter with 20-minute minimally invasive surgery
Health·

Urinary incontinence is not the fate of aging! 60-year-old woman regains laughter with 20-minute minimally invasive surgery

Cai Zhengyan, a urologist at China Medical University Hsinchu Hospital, explained that injecting biocompatible hydrogel filling material into the urethral wall through an endoscope can increase the closing force of the urethra. The treatment only takes about 20 minutes, and the patient is discharged the next day. It is suitable for patients with stress urinary incontinence.

自由时报
3 min read
Care Online》Don’t give up on advanced liver cancer! "Double immunotherapy" paid by health insurance can help "reverse" the course of the disease, a lazy guide with pictures and texts by specialists
Health·

Care Online》Don’t give up on advanced liver cancer! "Double immunotherapy" paid by health insurance can help "reverse" the course of the disease, a lazy guide with pictures and texts by specialists

Chen Baiyue, a gastrointestinal and hepatobiliary physician at Chiayi Christian Hospital, pointed out that dual immunotherapy has been included in health insurance benefits as one of the treatment options for advanced liver cancer. By combining two immune checkpoint inhibitors to activate the autoimmune system, about 20% of patients can have their tumors significantly shrunk or even reversed to the stage of surgical resection, and are less likely to suffer side effects of liver damage.

自由时报
3 min read
The Diabetes Health Education Association, Japan, South Korea and other countries jointly developed/Asia’s first weight-loss injection guidelines to be released as soon as January next year
Developing·

The Diabetes Health Education Association, Japan, South Korea and other countries jointly developed/Asia’s first weight-loss injection guidelines to be released as soon as January next year

The Diabetes Health Education Society plans to invite domestic societies to jointly publish Asia's first special guidelines on the side effects of slimming injections with Japan, South Korea and other Asian countries. The first draft is expected to be drafted by the end of November and published in international academic journals in January next year. The content covers situations such as drug withdrawal before surgery, dose conversion and overdose management.

自由时报
2 min read
There were 63 cases of adverse reactions of Slimming Injections reported this year / 39 cases were reported for weight loss purposes, more than 60%. Most of the symptoms were gastrointestinal diseases.
Health·

There were 63 cases of adverse reactions of Slimming Injections reported this year / 39 cases were reported for weight loss purposes, more than 60%. Most of the symptoms were gastrointestinal diseases.

According to statistics from the Food and Drug Administration, this year it received 63 reports of suspected adverse reactions to GLP-1 receptor agonist drugs, of which 39 were for weight loss and 24 were for diabetes treatment. Most of the symptoms were gastrointestinal diseases. The Food and Drug Administration has required pharmaceutical manufacturers to develop post-marketing safety research plans and risk assessment and control plans, and reminds the public that such injections are prescribed by doctors and should not be purchased and administered on their own.

自由时报
3 min read
《TAIPEI TIMES》 Guide on weight-loss drugs planned
Health·

《TAIPEI TIMES》 Guide on weight-loss drugs planned

The Taiwan Diabetes Education Association plans to work with domestic and regional partners to develop Asia's first GLP-1 drug side effect prevention and management guidelines, covering safe use in weight loss and diabetes management, which are expected to be published in international academic journals in January next year. Taiwan's Food and Drug Administration has received 63 reports of suspected adverse reactions involving GLP-1 receptor agonists this year, mainly gastrointestinal problems.

自由时报
2 min read
Two years after stopping the medication, my blood pressure is still normal! The new drug baxdrostat, which inhibits aldosterone, may be a new dawn for "surgery-free" treatment for certain patients with hypertension.
Developing·

Two years after stopping the medication, my blood pressure is still normal! The new drug baxdrostat, which inhibits aldosterone, may be a new dawn for "surgery-free" treatment for certain patients with hypertension.

A study led by Queen Mary, University of London found that after the new drug baxdrostat was used to treat patients with primary aldosteronism, some patients' blood pressure returned to normal after stopping the drug for up to two years, which is expected to "cure" hypertension. The findings were published in the New England Journal of Medicine and NICE is assessing whether the drug should be made available on the NHS.

自由时报
3 min read
More on this topic失智症